Taken together, these studies demonstrate that mesothelin is highly expressed in gastric and colon tumours as well as in cell lines, making them attractive candidates for mesothelin‐targeted CAR‐T cell therapies. The gene discussed is MSLN; the disease is colonic neoplasm.